MedTrace Logo

Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLC

NCT05218759 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-02-01

No results posted yet for this study

Summary

Exosomes detection for the prediction of the efficacy and adverse reactions of Anlotinib in patients with advanced NSCLC

Conditions

Interventions

DRUG

Anlotinib

anlotinib administration at a dose of 10 mg daily

Sponsors & Collaborators

  • 3D Medicines

    collaborator INDUSTRY

  • Shanghai Chest Hospital

    lead OTHER

Principal Investigators

  • Aiqin Gu, Chief physician · Shanghai Chest Hospital, Shanghai, China, 200030

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-21
Primary Completion
2025-05-31
Completion
2025-10-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05218759 on ClinicalTrials.gov